Erbitux (cetuximab) - Eli Lilly
5-fluorouracil - Generic mfg.
Braftovi (encorafenib) - Pfizer
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
irinotecan - Generic mfg.
Perjeta (pertuzumab) - Roche
Herceptin (trastuzumab) - Roche
Mektovi (binimetinib) - Pfizer
leucovorin calcium - Generic mfg.
SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Sep 10, 2026 - P3 | N=400 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting 
Enrollment closed • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF
http://clinicaltrials.gov/ct2/show/NCT03803553
 
Sep 10, 2026
 
Prev Next